新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 组学 » JAD:阿尔兹海默氏症血液检测获重大突破

JAD:阿尔兹海默氏症血液检测获重大突破

来源:生物谷 2016-09-01 23:27

图片摘自:www.express.co.uk

2016年9月2日 讯 /生物谷BIOON/ --近日,一项刊登在Journal of Alzheimer's Disease杂志上的研究报告中,来自卡迪夫大学等机构的研究者通过研究在开发诊断初期阿尔兹海默氏症的血液检测技术上取得了突破性的进展。该项研究由阿尔兹海默氏症协会提供资助。

文章中,研究人员对292名有早期记忆缺失迹象的个体的血液标本进行了研究,结果发现了一系列预测疾病的生物标志物,这些标志物或可帮助预测特定个体患阿尔兹海默氏症的风险。Paul Morgan教授说道,我们的研究证明了,我们有可能预测那些有轻度记忆问题的个体是否会在接下来的岁月里患阿尔兹海默氏症,当然我们也希望基于当前的研究来开发出新型简便的血液检测技术,从而更好地预测轻度记忆缺失或损伤的个体患阿尔兹海默氏症的可能性。

研究者对来出现常见记忆缺失症状的个体机体中的血液样本进行分析,测定了大量蛋白质的水平,这些蛋白质属于机体免疫系统的一部分,其可以驱动炎性发生,并且参与多种脑部疾病的发生。一年后当再次对这些个体进行评估时,大约有四分之一的个体发展成了阿尔兹海默氏症,同时相比未发展成为阿尔兹海默氏症的个体而言,这些患者机体血液中测定的三种蛋白质的水平也发生了明显的差异。

研究者Morgan补充道,阿尔兹海默氏症在英国影响着大约52万人的健康,而且患者的数量还在不断持续增长中,因此对于我们而言寻找新型方法尽可能早地诊断出阿尔兹海默氏症患者显得非常重要,而且这也将帮助我们在患者出现不可逆损伤之前开发出新型的治疗方法。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转发,转载需授权!点击  获取授权 。更多资讯请下载 生物谷APP.

Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease.

Hakobyan S1, Harding K2, Aiyaz M3, Hye A3, Dobson R3, Baird A4, Liu B4, Harris CL1, Lovestone S4, Morgan BP1.

There is a critical unmet need for reliable markers of disease and disease course in mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The growing appreciation of the importance of inflammation in early AD has focussed attention on inflammatory biomarkers in cerebrospinal fluid or plasma; however, non-specific inflammation markers have disappointed to date. We have adopted a targeted approach, centered on an inflammatory pathway already implicated in the disease. Complement, a core system in innate immune defense and potent driver of inflammation, has been implicated in pathogenesis of AD based on a confluence of genetic, histochemical, and model data. Numerous studies have suggested that measurement of individual complement proteins or activation products in cerebrospinal fluid or plasma is useful in diagnosis, prediction, or stratification, but few have been replicated. Here we apply a novel multiplex assay to measure five complement proteins and four activation products in plasma from donors with MCI, AD, and controls. Only one complement analyte, clusterin, differed significantly between control and AD plasma (controls, 295 mg/l; AD, 388 mg/l: p < 10- 5). A model combining clusterin with relevant co-variables was highly predictive of disease. Three analytes (clusterin, factor I, terminal complement complex) were significantly different between MCI individuals who had converted to dementia one year later compared to non-converters; a model combining these three analytes with informative co-variables was highly predictive of conversion. The data confirm the relevance of complement biomarkers in MCI and AD and build the case for using multi-parameter models for disease prediction and stratification.

相关会议推荐

2016 脑成像与神经退行性疾病研讨会

会议时间:2016.12.02-2016.12.03 会议地点:上海

会议详情:http://www.bioon.com/z/2016bs/

本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库